Navigation Links
GeneLink Reports First Quarter Gains
Date:5/11/2010

ORLANDO, Fla., May 11 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today reported financial results for the fiscal quarter ended March 31, 2010.

Financial Highlights:

  • Continued progress towards profitability: Quarterly operating loss reduced by 14% over Q4 2009
  • Comparable quarter gross profit improvement over Q1 2009 of 37%
  • Q1 Revenues of  $2,221,111, a 12.6% increase over Q1 2009

Gary Beeman, GeneLink's CEO stated, "The first quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins as GeneLink continued to make progress towards profitability in 2010, with operating losses dropping 14% as compared to the prior quarter.  In addition to continuing our investment in growing and improving the financial performance of our existing GeneWize sales operations, we are focusing on expanding the revenue base at GeneLink in market areas that we previously could not reach."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "The first quarter was notable not only for the continued reduction of losses, but more so for the addition of Gary Beeman as CEO.  Gary has already helped GeneLink expand its vision and aspirations in ways which will start to evidence themselves in the coming months in our product offerings, business partnerships, and financial performance."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading bioscienc
'/>"/>

SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
2. Winner Medical Reports Second Quarter Results for the Fiscal Year 2010
3. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
4. BMP Sunstone Reports First Quarter 2010 Financial Results
5. American Oriental Bioengineering Reports First Quarter 2010 Financial Results
6. OncoGenex Reports First Quarter Financial Results
7. Oncothyreon reports full year and fourth quarter 2009 financial results
8. Oncothyreon reports first quarter 2010 financial results
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
11. Anavex reports animal study results as lead Alzheimers compound approaches phase 1 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... On Thursday, September 11, 2014, the NASDAQ Composite ... finished the day 0.12% lower at 17,049.00, and the S&P ... based as seven out of ten sectors ended the session ... the day at 741.83, down 0.33%, while the index has ... coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
(Date:9/11/2014)... one atom thick sheet of carbon, can be randomly ... of graphene that could have a significant impact on ... it could provide an ultra-strong, non-corrosive coating for a ... solutions can be used to paint various surfaces ranging ... a simple chemical treatment, the resulting coatings behave like ...
Breaking Biology Technology:Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... (OTCBB:IAGX) announced today it has appointed Bill Toomey to ... the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer ... join our board and bring to us his extensive ... benefit greatly from his past experiences and high level ...
... BELL, Pa., June 30, 2011 Inovio Pharmaceuticals, Inc. ... the development of therapeutic and preventive vaccines against cancers ... compelling immune responses in a study of its multi-subtype ... proprietary vaccine delivery technology in sheep, the second large ...
... ORLEANS, June 29, 2011 Ochsner Health System has signed ... e ICU Program to enhance critical care -- a program ... of stay and save lives. As the only healthcare provider ... Ochsner will serve as a statewide resource to community and ...
Cached Biology Technology:Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 3Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 4Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 5Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 6Ochsner Health System will Offer First eICU Program in Louisiana 2Ochsner Health System will Offer First eICU Program in Louisiana 3
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... is no published account where hippopotamuses are demonstrably shown ... of water. But if they can,t swim, how did ... widely accepted models for the methods, patterns, and timing ... Cyprus, Crete, and Madagascar) may need to be reconsidered. ... the mainland are not currently supported by positive ...
(Date:9/15/2014)... the proteins in our cells cooperate with one another. ... of thousands of different proteins find the correct dancing ... body, brain and nervous system. A recent breakthrough at ... down the door and provided a look at the ... Professor emeritus Jens Jrgen Led of the University of ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Protein courtship revealed through chemist's lens 2Protein courtship revealed through chemist's lens 3
... at the second European Lung Cancer Conference shows ... small-cell lung cancer benefit in terms of overall ... Patients treated with hyperfractionated or accelerated radiotherapy ... over a shorter period of time. The benefit ...
... radiotherapy using real-time X-ray images has allowed French doctors to ... liver cancers while minimizing harm to nearby healthy tissue, researchers ... this study we show that it is possible and very ... at any time before or during treatment in terms of ...
... In this latest image acquired by ESA,s Envisat on Thursday ... Gulf of Mexico can be seen as a dark blue ... the oil spill five times larger than first estimated ... coast, threatening environmental disaster. , As efforts are being made ...
Cached Biology News:Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer 2Oil spill in the Gulf of Mexico nears the coast 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Biology Products: